PTC Therapeutics (PTCT) director exercises options, sells 15,167 shares

Rhea-AI Filing Summary

PTC Therapeutics director Stephanie Okey exercised stock options and sold shares in a pre-planned transaction. On March 10, 2026, she exercised options to acquire 15,167 shares of common stock at an exercise price of $33.63 per share.

On the same date, she sold 15,167 common shares in open-market transactions at a sale price of $70.00 per share pursuant to a written Rule 10b5-1 trading plan adopted on November 24, 2025. Following these transactions, she holds 8,000 shares of PTC Therapeutics common stock directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Okey Stephanie

(Last) (First) (Middle)

C/O PTC THERAPEUTICS, INC.

500 WARREN CORPORATE CENTER DRIVE

(Street)

WARREN NJ 07059

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PTC THERAPEUTICS, INC. [ PTCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/10/2026		M(1)		1,167	A	$33.63	9,167	D
Common Stock	03/10/2026		S(1)		1,167	D	$70	8,000	D
Common Stock	03/10/2026		M(1)		14,000	A	$33.63	22,000	D
Common Stock	03/10/2026		S(1)		14,000	D	$70	8,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$33.63	03/10/2026		M(1)			1,167	(2)	12/13/2028	Common Stock	1,167	$0	0	D
Stock Option (Right to Buy)	$33.63	03/10/2026		M(1)			14,000	(2)	12/13/2028	Common Stock	14,000	$0	0	D

Explanation of Responses:

1. This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 24, 2025.

2. Currently exercisable.

	/s/ Avraham S. Adler, Attorney-in-Fact	03/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did PTC Therapeutics (PTCT) director Stephanie Okey report?

Director Stephanie Okey reported exercising options and selling shares. She exercised options for 15,167 PTC Therapeutics common shares at $33.63 and sold 15,167 shares at $70.00 on March 10, 2026 under a pre-planned Rule 10b5-1 trading plan.

How many PTC Therapeutics (PTCT) shares did Stephanie Okey sell and at what price?

Stephanie Okey sold 15,167 PTC Therapeutics common shares. The reported sale price was $70.00 per share on March 10, 2026. These were open-market or private transactions disclosed with transaction code S in the Form 4 filing.

What stock options did Stephanie Okey exercise in the latest PTCT Form 4?

She exercised stock options covering 15,167 underlying PTC Therapeutics common shares at an exercise price of $33.63 per share. The options were described as currently exercisable and had an expiration date of December 13, 2028 before being fully exercised.

How many PTC Therapeutics (PTCT) shares does Stephanie Okey own after these transactions?

After the reported transactions, Stephanie Okey directly owns 8,000 PTC Therapeutics common shares. This post-transaction holding reflects the position remaining following her option exercises and the sale of 15,167 shares on March 10, 2026.

Were Stephanie Okey’s PTCT share sales made under a Rule 10b5-1 trading plan?

Yes, the filing states the transactions were effected under a written Rule 10b5-1 plan adopted on November 24, 2025. Rule 10b5-1 plans pre-schedule trades, indicating these sales were planned in advance rather than timed discretionarily.

What does transaction code M mean in Stephanie Okey’s PTCT Form 4?

Transaction code M indicates an exercise or conversion of a derivative security, here stock options. In this Form 4, Okey used code M for exercising options into 15,167 PTC Therapeutics common shares at an exercise price of $33.63 per share.